Macrolide antibiotics and Pseudomonas aeruginosa infection;Macrolides et infection a Pseudomonas aeruginosa

Archives de Pediatrie

Volumn 7, Issue SUPPL. 3, 2000, Pages

  Guillot, M ^a   Eckart, P ^a   Desrosieres H ^a   Brouard, J ^b  

^a HÔPITAL DU BOCAGE   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Macrolides; Pseudomonas aeruginosa

Indexed keywords

MACROLIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CHRONIC DISEASE; CONFERENCE PAPER; DRUG EFFECT; HUMAN; IMMUNOREGULATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; ARTICLE; GRAM NEGATIVE INFECTION; PATHOGENICITY; VIRULENCE;

ANTI-BACTERIAL AGENTS; HUMANS; MACROLIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE;

EID: 0034202867     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)80179-7     Document Type: Conference Paper

References (68)

1. Bryskier A. Les macrolides de demain, intérêt en thérapeutique. Pyrexie 1998 ; 2 : 353-60.
2. Thabaut A. Le spectre d'activité antibactérienne des macrolides. Lettre Infectiologue 1995 ; HS : 17-22.
3. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Rashima A. Long term low dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991 ; 58 : 145-9.
4. Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, et al. In vitro P. aeruginosa virulence ENSE factor inhibited by macrolides antibiotics. Antimicrob Agent Chemother 1994 ; 38 : 528-33.
5. Bryskier A, Agouridas C, Gasc JC. Classification of macrolide antibiotics. In: Bryskier AJ, Butzler JP, Neu HC, Tulkens PM, eds. Macrolides, chemistry, pharmacology and clinical uses. Paris: Arnette-Blackwell; 1993. p. 5-66.
6. Soussy CJ, Cluzel R, Courvalin P. Definition and determination of vitro antibiotic susceptibility break points in France. Eur J Clin Microbiol Infect Dis 1994 ; 13 : 238-46.
7. Thabaut A. Les macrolides en 1992 ; structure et classification, activité antibactérienne, pharmacocinétique. Lettre Infectiologue 1992 ; 7 : 585-9.
8. Williams JD, Maskell JP, Shain H, Chrysos G, Septon AM, Fraser HY, et al. Comparative in vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother 1992 ; 30 : 27-37.
9. Williams JD. Spectrum of activity of erithromycin. Eur J Clin Microbiol Infect Dis 1991 ; 10 : 813-20.
10. Rouveix B, Giroud JP. Diffusion pulmonaire des antibiotiques : intérêts et limites pharmacologiques. Pédiatrie 1999 ; 2 HS : 78-81.
11. Michel Briand Y. Infections à bacille pyocyanique. Encycl Méd Chir (Éditions techniques, Paris). Maladies infectieuses, 81-36-A-101. 1992: 1-14.
12. Lenoir G. P. aeruginosa et mucoviscidose. Rev Pneumol Clin 1995 ; 51 : 151-8.
13. Prince A. Update on the pathogenesis of Pseudomonas aeruginosa infections. Symp Ses Sum 1993 ; S3 : 81-2.
14. Vasil ML. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. Pediatr Res 1986 ; 108 : 800-5.
15. Gilligan P. Microbiology of airway disease in patients with cystic flbrosis. Clin Microbiol Rev 1991 ; 4 : 35-51.
16. Munck A, Bingen E. Mucoviscidose, épidémiologie des infections. Pédiatrie 1999 ; HS 2 : 82-6.
17. Woods DE, Sokol PA, Bryan LE, Storey DG, Mattingly SJ, Vogel H, et al. In vivo regulation of virulence in Pseudomonas aeruginosa associated with genetic rearrangement. Infect Dis 1991 ; 163 : 143-9.
18. Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, et al. Comparative in vitro exoenzyme suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994 ; 38 : 528-33.
19. Baker NR, Minor V, Real C, Sharabadi MS, Simpson DA, Woods DE. Pseudomonas aeruginosa exoenzyme S is an adhesin. Infect Immun 1987 ; 55 : 1517-22.
20. Ramsey BW. Drug therapy management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996 ; 335 : 179-88.
21. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung in jury: prognosis and pathogenetic significance. Am J Respir Crit Care Med 1997 ; 155 : 1187-205.
22. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998 ; 157 : S123-9.
23. Tateda K, Ishii Y, Hirakata Y, Matsumoto J, Ohna A, Yamaguchi K. Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICS of macrolide antibiotics and their relation to enhanced serum sensitivity J Antimicrob Chemother 1994 ; 34 ; 931-42.
24. Abdallah MA, Hennard C, Linget C, Ocaktan A. Transport du fer et rôle des pyoverdines dans la virulence de Pseudomonas aeruginosa. Incidences thérapeutiques. Pathol Biol 1991 ; 39 : 600-5.
25. Bajolet-Laudinat O, Plotkowski MC, Puchelle E. Facteurs d'adhérence de Pseudomonas aeruginosa au tractus respiratoire. Lettre Infectiologue 1994 ; 8 : 260-5.
26. Saiman L, Sadoff J, Prince A. Cross reactivity of Pseudomonas aeruginosa anti pilin monoclonal antibodies with heterogeneous strains of P. aeruginosa and P. cepacia. Infect Immun 1989 ; 57 : 2764-70.
27. Marty N, Dournes JL, Chabanon G, Montrozier H. Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non mucoid Pseudomonas aeruginosa. FEMS Microbiol Lett 1992 ; 98 : 35-44.
28. Mary TB, Shinabarger D, Maharaj R, Kato J, Shu L, De Vault JD, et al. Alginate synthesis by Pseudomonas aeruginosa, a key pathogenic factor in chronic pulmonary infection of cystic fibrosis patients Clin Microbiol Rev 1991 ; 4 : 194-206.
29. Pedersen SS. Biological properties of mucoid Pseudomonas aeruginosa and alginate. APMIS 1992 ; 28 : S39-44.
30. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H. Clinical effect of low dose, long term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis 1987 ; 25 : 632-42.
31. Yamamoto M. Therapeutic effect of erythromycin in patients with DDE - double blind trial (Japanese). A mucol report on the study of diffuse disseminated interstitiel lung disease. Grant in aid from the ministry of Health and Welfare in Japan 1991 ; 18-20.
32. Takeda H, Miura H, Kawahira M, Koyabashi H. Long term administration study on TE O31 A-56268 in treatment of diffuse panbronchiolitis. J Jpn Assoc Infect Dis 1989 ; 63 : 71-8.
33. Ashitani J, Doutsu Y, Taniguchi H, Ii T, Matsukura SA. A case of diffuse panbronchiolitis relieved rapidly by the treatment of roxithromycin (Japanese). J Jpn Assoc Infect Dis 1992 ; 66 : 657-8.
34. Koyabashi H, Takeda H, Sakayoris S, Kawakami Y, Otsuka Y, Tamura M. Study on azithromycin in treatment of diffuse panbronchiolitis. J Jpn Assoc Infect Dis 1995 ; 69 : 711-22.
35. Kit AA, Sawari M, Oku D. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. Antimicrob Agents Chemother 1991 ; 27 : 273-84.
36. Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, et al. Comparative in vitro exoenzyme. Suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994 ; 38 : 528-33.
37. Sakata K, Yajima H, Tanaka K, Sakamoto Y, Yamamoto K, Yoshida A, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 1993 ; 148 : 1061-5.
38. Yamasaki T. Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium: the effect of antimicrobial agents. J Jpn Assoc Infect Dis 1990 ; 64 : 575-83.
39. Tateda K, Ishii Y, Hirakata K. Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICS of macrolide antibiotics and their relation to enhanced serum sensitivity. J Antimicrob Chemother 1994 ; 34 : 931-42.
40. Lapointe JR, Bourget C, Lafleur L, Lagace J, Montplaisir S. Mucoid and pigmentation characters can be suppressed by non anti-Pseudomonas aeruginosa antibiotics in cystic fibrosis: a report of promising preliminary results. Drugs Exp Clin Res 1988 ; 14 : 501-10.
41. Dupont MJ, Lapointe JR. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum to Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother 1995 ; 36 : 231-6.
42. Koyabashi H. Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. J Infect Chemother 1995 ; 1 : 1-15.
43. Hosoyama T, Yuge T, Takahashi S, Suzuki T, Okubo T, Iyobe S, et al. Inhibitory effect of antimicrobial agents on alginate production in Pseudomonas aeruginosa. J Antibiot 1999 ; 52 : 65-7.
44. Koyabashi H. Bacterial biofilm. Kansensho 1991 ; 21 : 161-78.
45. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993 ; 37 : 1749-55.
46. Kondoh K, Hashiba M, Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol 1996 ; S 525 : 56-60.
47. Ichimiya T, Yamasaki T, Nasu M. In vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 1994 ; 34 : 331-41.
48. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother 1996 ; 40 : 2271-5.
49. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997 ; 52 : 915-8.
50. Goswami SK, Kivity S, Maron Z. Erythromycin inhibits respiratory glycoconjugate secretion from humain airways in vitro. Am Rev Respir Dis 1990 ; 141 : 72-8.
51. Tamaoki J, Isono K, Sakay N, Kanemura T, Konno K. Erythromycin inhibits C1 secretion across canine tracheal epithelial cells. Eur Respir J 1992 ; 5 : 234-8.
52. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vitro induction of liver P. glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995 ; 133 : 269-76.
53. Altschuler EL. Azithromycin, the multidrug resistant protein and cystic fibrosis. Lancet 1998 ; 35 : 1286.
54. Labro MT. Macrolides et immunité. Lettre Infectiologue 1995 HS septembre ; 10-3.
55. Ras GJ, Anderson R, Taylor GW. Antioxydative properties of macrolides antibiotics. Antimicrob Agents Chenother 1992 ; 36 : 1236-40.
56. Plewig G, Schopf E. Anti-inflammatory effects of antimicrobial agents: an in vitro study. J Invest Dermatol 1975 ; 65 : 532-6.
57. Nelson S, Summer WR, Terry PB, Warr GA, Jakab GJ. Erythromycin induced suppression of pulmonary antibacterial defences: a potential mechanism of superinfection in the lung. Am Rev Respir Dis 1987 ; 136 : 1207-12.
58. Ichikawa Y, Ninomiya H, Koga H, Tanaka M, Kinoshita M, Tokunaga N, et al. Erythromycin reduces neutrophils and neutrophil derived elastalytic like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992 ; 146 : 196-203.
59. Sakito O, Kadota J, Kohno S. Interleukin 1 β, tumor necrosis factor α and interleukin in broncho-alveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996 ; 63 : 42-8.
60. Kadota J, Sakito O, Kohno S. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993 ; 147 : 153-9.
61. Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992 ; 146 : 473-8.
62. Sugiyama Y, Sugama Y, Takenchi K, Kudoh S, Kitamura S. Analysis of peripheral lymphocyte subsets and changes due to erythromycin therapy in patients with diffuse panbronchiolitis. Jpn J Thorac Dis 1990 ; 28 : 1574-80.
63. Yanagihara K, Timmo K, Sawai T, Hirakata Y, Kadota J, Koga H. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997 ; 155 : 337-42.
64. Roche Y, Gougerot-Pocidalo MA, Fay M, Forest N, Pocidalo JJ. Macrolides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J Antimicrob Chemother 1986 ; 17 : 195-203.
65. Keicho N, Kudoh S, Yotsumoto H, Akagawa KS. Antilymphocytic activity of erythromycin distinct from that of FK 506 or cyclosporin A. J Antibiot 1993 ; 46 : 1406-13.
66. Mikasa K, Sawaki M, Konishi M, Egawa S, Yoneda T, Yagyu Y. The effect of erythromycine treatment of natural killer cell activity in patient with chronic lower respiratory tract infection. J Jpn Assoc Infect Dis 1989 ; 63 : 811-5.
67. Jaffe A, Francis J, Rosenthal M, Bush A. Long term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998 ; 351 : 420.
68. Guillot M. Macrolides et Pseudomonas aeruginosa. Lettre Mucoviscidose 1998 ; 43 : 3.